A new, collaborative whole-genome sequencing (WGS) effort has been launched with the goal of fostering new insights into ALS by linking genetic, clinical and pathological data from ALS patients. Human tissue samples from deceased ALS patients will be provided through the Target ALS Postmortem Tissue Core, a multi-center tissue bank located at several universities throughout the United States. The sequencing will be conducted at the New York Genome Center (NYGC), and the genetic data will be linked to patients’ clinical information and tissue samples, thus providing a wealth of new information that integrates genetics, clinical data, and tissue pathology. In addition, the ALS Association and TargetALS have announced an expansion of the TargetALS tissue core to include biofluids from people with ALS, which will also be incorporated into the genetic analysis efforts at the NYCG.
Click here to read more.